Mangrove Partners Adverum Biotechnologies, Inc. Transaction History

Mangrove Partners

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2018 May 15, 2018	SELL	$3.65 - $7.95 $1.55 Million - $3.38 Million	-424,538 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$2.85 - $3.95 $30,495 - $42,265	10,700 Added 2.59%	424,538 $1.49 Million
Q3 2017 Nov 14, 2017	BUY	$2.45 - $3.65 $1.01 Million - $1.51 Million	413,838	413,838 $1.51 Million

2.53M

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $771M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Mangrove Partners, based on Form 13F filings with the SEC.

Stay updated on Mangrove Partners with notifications on news.